| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Product Type | |
| Promoter | |
| Reporter | |
| Selection Marker | Blasticidin, N/A, Puromycin |
| Shipping | |
| Species |
Background
KRAS is a proto-oncogene encoding a small GTPase that acts as a molecular switch in growth-factor signaling. Cycling between an active GTP-bound and inactive GDP-bound state, KRAS relays signals from receptor tyrosine kinases to downstream effectors, principally the RAF-MEK-ERK and PI3K-AKT pathways, controlling cell proliferation, differentiation, and survival. Oncogenic point mutations, most commonly at codons 12, 13, and 61, lock KRAS in the active GTP-bound state, producing constitutive signaling. Such mutations are among the most frequent in human cancer, occurring at high rates in pancreatic, colorectal, and lung adenocarcinomas, and drive tumor initiation and progression. KRAS is therefore a central focus of cancer biology and targeted-therapy research.
Product Description & Applications
The KRAS (Wild Type and Mutant) ORF cDNA Lentivirus delivers the human KRAS open reading frame (transcript variant a) for stable overexpression in mammalian cells, available as wild type or as common oncogenic mutants. An EF1a promoter drives expression of KRAS fused to a C-terminal V5 tag, linked via self-cleaving peptides to a fluorescent reporter (GFP or RFP) or firefly luciferase and a drug-selection marker (puromycin or blasticidin); in some constructs a PGK promoter drives the reporter and selection cassette separately. The lentiviral vectors are optimized for high expression and reliable genome integration, and the particles efficiently transduce difficult-to-transfect cells, including primary and thawed cultures, supporting stable cell line generation for studies of RAS signaling and oncogenic transformation. ORF integrity is verified by sequencing and expression confirmed by transient transfection.
About This Product
This ORF cDNA lentivirus enables stable overexpression of KRAS (NCBI Accession: NM_033360) in mammalian cells via a third-generation, VSV-G pseudotyped delivery system. The ORF cDNA is fused to a C-terminal epitope tag (V5, Myc, or HA) and expressed under a strong constitutive promoter (EF1a). Reporter and selection marker components (Firefly Luciferase, GFP, RFP; Blasticidin, Puromycin) are co-expressed via self-cleaving P2A peptides, enabling independent protein production without fusion-tag artifacts.
Ultra-purification by PEG precipitation and sucrose gradient centrifugation yields high-titer particles suitable for primary cells, suspension cultures, and stem cells. Stable polyclonal cell lines are established within 10–14 days by antibiotic selection or FACS sorting. For in vivo applications, the serum-free formulation and VSV-G envelope support direct administration or further concentration for stereotactic injection.
Can't find the lentiviral construct you need, or want to adjust key design elements? Contact us to discuss custom LV design and optional add-ons.
Common customization requests
- Insert / payload: replace the gene/sequence, swap to a different isoform, add mutations, or optimize cloning features.
- Expression design: change promoter (e.g., CMV/EF1α/PGK), add enhancers, or adjust regulatory elements.
- Reporters: add/swap GFP/RFP/mCherry/luciferase (single or dual reporters where applicable).
- Selection markers: add/swap puromycin/blasticidin/neomycin or fluorescent selection options.
- Vector format: switch between OE, shRNA, CRISPR (sgRNA/Cas systems), or control vectors (where supported).
Add-ons you can request
- Control viruses: empty vector, non-targeting shRNA, reporter-only controls, or matched backbone controls.
- Packaging / format: concentration options, aliquoting, or custom fill volume for screening workflows.
- Documentation: construct map/sequence confirmation package (as available) and batch documentation.
What to include in your request
- Target cell type/model (cell line or primary cells) and intended readout (reporter, knockdown, OE, etc.)
- Insert sequence (FASTA) or reference ID, plus any required tags/mutations
- Promoter, reporter, and selection marker preferences
- Desired scale and preferred format (aliquots / concentration requests)
Email us at support@biohippo.com or use the Talk to a Scientist request form.
